Last reviewed: June 25, 2026
Last updated: June 25, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide works by activating GLP-1 receptors in your brain and gut, triggering signals that decrease appetite and food cravings while improving blood sugar control. Clinical trials show patients using semaglutide lose 15–22% of their body weight over 68 weeks. PlexusDx delivers compounded semaglutide injections from licensed 503A pharmacies to all 50 states, with personalized dosing and no insurance required.
What Is Semaglutide and How Does It Work
Semaglutide is a medication that belongs to a class called GLP-1 receptor agonists. It mimics glucagon-like peptide-1, a hormone your pancreas naturally produces to regulate blood sugar and appetite. When semaglutide binds to GLP-1 receptors in your brain, it activates the satiety center—the part that tells you when you are full—and reduces the hunger-signaling hormone ghrelin. This dual action helps you eat less without fighting constant cravings.
The medication also slows gastric emptying, meaning food stays in your stomach longer and you feel satisfied on smaller meals. Research shows semaglutide can lower fasting blood glucose, improve insulin sensitivity, and reduce cardiovascular risk in people with obesity or type 2 diabetes. Because semaglutide addresses the neurological roots of overeating rather than relying on willpower alone, many patients find sustained weight loss more achievable than with diet and exercise alone.
Clinical Evidence for Semaglutide Weight Loss Results
The STEP trials—the largest clinical studies of semaglutide for weight loss—enrolled over 4,500 adults with obesity or overweight and at least one weight-related condition. Participants who received semaglutide 2.4 mg weekly lost an average of 15.3 kg (33.7 pounds) over 68 weeks, compared to 2.6 kg in the placebo group. At the 2.4 mg dose, approximately 50% of patients achieved a weight loss of at least 15%, and 35% lost 20% or more of their baseline body weight.
These results held steady across diverse age groups, ethnicities, and BMI levels, demonstrating broad effectiveness. Weight loss typically begins within the first 4 weeks and continues to improve through week 68. Follow-up data show that when patients stop semaglutide, weight tends to return gradually, underscoring the importance of ongoing therapy for sustained outcomes. Most importantly, the medication improved not just weight but also blood pressure, cholesterol, and markers of inflammation linked to heart disease and diabetes.
Understanding GLP-1 Receptor Genetics and Your Response
Not everyone responds identically to semaglutide—individual genetic variation in GLP-1 receptor function influences how effectively the medication works for you. Key genetic variants such as GLP1R rs6923761 and GIPR rs1800437 affect how efficiently your body's GLP-1 and GIP receptors bind medication and signal appetite reduction. Additionally, genetic differences in the FTO and MC4R genes influence your baseline appetite set point and energy metabolism, shaping your weight loss trajectory.
PlexusDx offers the Precision Peptide Genetic Test, which maps 14 peptide pathways and 49 peptides across 150+ genetic insights to identify your unique predisposition to hunger signals and medication response. Understanding your genetic profile helps PlexusDx clinicians personalize your semaglutide dose and potentially recommend combination therapy or alternative GLP-1 compounds if needed. This precision approach removes guesswork and helps you achieve faster, more predictable weight loss results aligned with your biology.
Semaglutide Dosing, Side Effects, and What to Expect
Semaglutide treatment begins with a low starter dose of 0.25 mg injected once weekly, then increases gradually every four weeks (0.5 mg, 1 mg, 1.7 mg, 2.4 mg) until reaching your target maintenance dose. This slow titration allows your body to adapt and minimizes side effects. Most patients tolerate the medication well, with nausea being the most common initial side effect, typically mild and lasting only a few days as your body adjusts. Nausea rates decrease significantly by week four as you progress through dose escalation.
Other potential side effects include constipation, decreased appetite for favorite foods, and occasional heartburn—all manageable with dietary adjustments and hydration. Serious side effects are rare but include pancreatitis, gallbladder disease, and thyroid concerns; your PlexusDx clinician will screen for these risks before starting. Importantly, your dose may need to increase over time as your body continues to adapt, but your price at PlexusDx remains flat—starting at $149 per month regardless of dose level. This transparent pricing structure ensures you never face surprise costs as your treatment evolves.
Compounded vs. Brand-Name Semaglutide: Cost and Access
Brand-name semaglutide (Wegovy®, Ozempic®) costs $900–$1,500 per month without insurance, and many insurance plans deny coverage for weight loss without documented diabetes or cardiovascular disease. PlexusDx compounded semaglutide offers the same active pharmaceutical ingredient but sourced from licensed 503A compounding pharmacies and delivered at significantly lower cost—starting at just $149 per month. Compounded medications are not FDA-approved but are legally manufactured under strict USP standards and quality controls equivalent to brand-name products.
PlexusDx serves all 50 states with no insurance required, no membership fees, and HSA/FSA eligibility, making semaglutide accessible to anyone serious about weight loss. Your first-month subscription includes unlimited messaging with your clinician to discuss dosing, side effects, and progress. If you want deeper personalization, adding the Precision Peptide Genetic Test ($99 add-on after first month) identifies your genetic predispositions and guides your clinician toward the most effective dose and protocol for your unique biology. With PlexusDx, affordability and precision work together.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
How quickly will I lose weight with semaglutide?
Most patients begin losing weight within 2–4 weeks of starting semaglutide, with steady progress over 12–16 weeks as your dose increases. Clinical trials show average weight loss of 15–22% of body weight over 68 weeks. Individual results vary based on genetics, lifestyle, and adherence; PlexusDx clinicians track your progress monthly and adjust your dose or protocol as needed.
Is compounded semaglutide as effective as brand-name Wegovy®?
Yes. Compounded semaglutide contains the identical active ingredient and works through the same mechanism as brand-name products. The difference is source and cost: PlexusDx sources from licensed 503A compounding pharmacies and passes savings directly to you at $149/month, while brand-name Wegovy® costs $900–$1,500 monthly and requires insurance or out-of-pocket payment.
Can I use semaglutide if I don't have diabetes?
Absolutely. Semaglutide is FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition such as hypertension or sleep apnea. PlexusDx serves patients across all 50 states regardless of insurance status or diabetes diagnosis.
What are the most common side effects and how long do they last?
Nausea is the most common side effect, typically mild and resolving within a few days as your body adjusts. Constipation and decreased appetite for regular foods also occur but improve with hydration and dietary fiber. Serious side effects like pancreatitis are rare; PlexusDx screens for contraindications before you start therapy.
How does the Precision Peptide Genetic Test help my weight loss?
The PlexusDx Precision Peptide Genetic Test ($99 add-on) identifies your genetic variants in GLP1R, GIPR, FTO, and MC4R genes—all linked to appetite control and medication response. This map of 150+ genetic insights helps your clinician personalize your semaglutide dose, predict side effect risk, and recommend combination therapy or alternative GLP-1 compounds for faster, more predictable results tailored to your biology.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Will I Lose Weight on Ozempic Without Exercise?
Where on the Arm to Inject Ozempic: A Comprehensive Guide